Furthermore, selective HDAC3 inhibitors restored immune surveillance by reactivating BCL6-repressed INF pathway and antigen presentation genes in lymphoma cells, enabling T-cells to recognize and kill them, especially in the presence of CREBBP mutation (Mondello et al., 2020). Here, HDAC3 is linked to lymphoma.